BIOGEN for BIOGEN
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 16, 2009 | $300,000 | Replaced |
| 2nd Quarter - Amendment | Jul 28, 2009 | $300,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Advocacy for appropriate reimbursement and payment rates for biologics under the Medicare and Medicaid programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Taxation/Internal Revenue Code TAX
Advocacy related to corporate tax policies, including deferral and R&D credit issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Copyright/Patent/Trademark CPT
Patent Reform -- S. 515 and HR 1260 -- Support for modernizing the patent system while ensuring the ongoing strength and value of intellectual property for biotechnology, especially related to damages provisions, inequitable conduct, and post-grant/second window.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Health Issues HCR
1) Biosimilars, including S 1695(from the 110th Congress), HR 1427, HR 1548, and S 726 -- Support for passage/enactment of legislation to create a pathway for the approval of biosimilars that protects patient safety and innovation. 2) Health care reform -- Support legislative efforts to expand access to health care insurance and protect innovation. 3) S. 301-- Advocating for gift disclosure requirements that provide appropriate transparancy and protect proprietary business information. 4) HR 1 -- Comparative Effectiveness Research -- Advocacy in support of comparative effectiveness research used to inform and improve clinical decision making and health outcomes; opposed to using such research for cost containment or denial of coverage.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.